-
公开(公告)号：EP3362445A1
公开(公告)日：2018-08-22
申请号：EP16855690.0
申请日：2016-10-11
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： KIM, Yuntae , LEE, Chang Sik , OH, Jung Taek , SONG, Hyeseung , CHOI, Jin , LEE, Jaeyoung
IPC: C07D413/04 , C07D271/10 , C07D271/06 , C07C211/33 , C07C211/35 , A61K31/4245 , A61K31/506
CPC classification number: C07D271/10 , A61K31/4245 , C07D413/04 , C07D413/14
Abstract: The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.
-
2.发明公开NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开中性粒细胞坏死因子乙酰胆碱酯酶（HDAC） - 抗生素在药物化合物ZUSAMMENSETZUNGEN DAMIT
公开(公告)号：EP3080125A1
公开(公告)日：2016-10-19
申请号：EP14869323.7
申请日：2014-12-12
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Changsik , YANG, Hyun-mo , LEE, Changkon , BAE, Miseon , KIM, Soyoung , CHOI, Youngil , HA, Nina , LEE, Jaekwang , OH, Jungtaek , SONG, Hyeseung , KIM, Ilhyang , CHOI, Daekyu , MIN, Jaeki , LIM, Hyojin , BAE, Daekwon
IPC: C07D471/04 , C07D487/04 , C07D401/04 , A61K31/437
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
Abstract translation: 本发明涉及新颖的氮杂吲哚衍生物，更具体地说，涉及具有组蛋白脱乙酰酶（HDAC）抑制活性的新型氮杂吲哚衍生物，其异构体，药学上可接受的盐，其水合物或溶剂合物，其用于制备药物组合物的用途， 含有该组合物的药物组合物，使用该药物组合物治疗疾病的方法，以及制备该新颖的氮杂吲哚衍生物的方法。 根据本发明的新颖的氮杂吲哚衍生物是选择性组蛋白脱乙酰酶（HDAC）抑制剂，可用作治疗恶性肿瘤疾病，炎症性疾病，类风湿性关节炎和神经变性疾病的药剂。
-
3.发明公开
公开(公告)号：EP4208461A1
公开(公告)日：2023-07-12
申请号：EP21863810.4
申请日：2021-09-01
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Chang Sik , OH, Jung Taek , YUN, Hokeun , SONG, Hyeseung , KIM, Hyunjin Michael
IPC: C07D413/10 , A61K31/4245 , A61K31/4439 , A61K31/444 , C07D413/14 , C07D471/10
-
公开(公告)号：EP3080125B1
公开(公告)日：2018-10-10
申请号：EP14869323.7
申请日：2014-12-12
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Changsik , YANG, Hyun-mo , LEE, Changkon , BAE, Miseon , KIM, Soyoung , CHOI, Youngil , HA, Nina , LEE, Jaekwang , OH, Jungtaek , SONG, Hyeseung , KIM, Ilhyang , CHOI, Daekyu , MIN, Jaeki , LIM, Hyojin , BAE, Daekwon
IPC: C07D471/04 , C07D519/00 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
-
公开(公告)号：EP3331864A2
公开(公告)日：2018-06-13
申请号：EP16833369.8
申请日：2016-08-04
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Jaekwang , KIM, Yuntae , LEE, Chang Sik , SONG, Hyeseung , GWAK, Dal-Yong , LEE, Jaeyoung , OH, Jung Taek , LEE, Chang Gon , KIM, II Hyang
IPC: C07D271/10 , C07D413/12 , A61K31/4245 , A61K31/5377 , A61K31/497
CPC classification number: C07D271/10 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/10 , C07D491/10
Abstract: The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.
-
6.发明公开
公开(公告)号：EP4504713A1
公开(公告)日：2025-02-12
申请号：EP23785033.4
申请日：2023-04-06
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Chang Sik , OH, Jung Taek , SONG, Hyeseung , KIM, Hyunjin Michael
IPC: C07D271/10 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/4995 , A61P35/00 , A61P29/00 , A61P37/00 , A61P25/28 , C07D413/12
-
公开(公告)号：EP3976602A1
公开(公告)日：2022-04-06
申请号：EP20815468.2
申请日：2020-05-29
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Chang Sik , OH, Jung Taek , YUN, Hokeun , SONG, Hyeseung , KIM, Hyunjin Michael
IPC: C07D413/06 , C07D413/10 , C07D413/14 , A61K31/4439 , A61K31/4245 , A61K31/4725 , A61K31/517 , A61P31/00 , A61P3/00 , A61P25/00
-
8.发明公开HETEROCYCLICALKYL DERIVATIVE COMPOUNDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开杂环化合物衍生物化合物作为选择性活性的脱乙酰酶抑制剂和包含该化合物的药物组合物
公开(公告)号：EP3297992A1
公开(公告)日：2018-03-28
申请号：EP16800269.9
申请日：2016-05-20
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Changsik , LEE, Jaekwang , SONG, Hyeseung , BAE, Daekwon , HA, Nina , KIM, Il Hyang
IPC: C07D241/04 , C07D211/34 , A61K31/4965 , A61K31/435
Abstract: The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.
-
9.发明公开
公开(公告)号：EP4288419A1
公开(公告)日：2023-12-13
申请号：EP22784261.4
申请日：2022-04-07
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Chang Sik , OH, Jung Taek , SONG, Hyeseung , KIM, Hyunjin Michael
IPC: C07D271/10 , A61K31/5377 , A61K31/496 , A61K31/541 , C07D413/04 , C07D413/12 , C07D487/10 , C07D491/107 , C07D471/10
-
10.发明公开
公开(公告)号：EP3976604A1
公开(公告)日：2022-04-06
申请号：EP20814548.2
申请日：2020-05-29
Applicant: Chong Kun Dang Pharmaceutical Corp.
Inventor： LEE, Chang Sik , OH, Jung Taek , YUN, Hokeun , SONG, Hyeseung , KIM, Hyunjin Michael
IPC: C07D413/10 , C07D413/06 , C07D417/14 , A61K31/454 , A61K31/5377 , A61K31/444 , A61K31/517 , A61K31/4245 , A61K31/427 , A61P35/00
